Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
Shuo Li, Zorawar S. Noor, Weihua Zeng, Mary L. Stackpole, Xiaohui Ni, Yonggang Zhou, Zuyang Yuan, Wing Hung Wong, Vatche G. Agopian, Steven M. Dubinett, Frank Alber, Wenyuan Li, Edward B. Garon, Xianghong Jasmine Zhou
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Genomics and Diagnostics · PARP inhibition in cancer therapy · Cancer Immunotherapy and Biomarkers
Correction to: Nature Communications 10.1038/s41467-021-24457-2, published online 7 July 2021
In the version of the article initially published, the Competing interests section was incomplete and has now been expanded in the HTML and PDF versions of the article to: “X.J.Z., W.L., and W.H.W. are co-founders of EarlyDiagnostics. X.J.Z and W.H.W serve on the Board of Directors for EarlyDiagnostics. X.J.Z. has an executive leadership position at EarlyDiagnostics. S.M.D. is a scientific advisor to EarlyDiagnostics. X.N., S.L., and M.L.S. are employees of EarlyDiagnostics. S.L., W.Z., M.L.S., X.N., Y.Z., S.M.D. have stock options with EarlyDiagnostics. X.J.Z., W.L., W.H.W., and F.A. are stockholders of EarlyDiagnostics. W.Z., Y.G., and W.L. are consultants for EarlyDiagnostics. X.J.Z., S.L. and W.L. are inventors on a patent application submitted by the Regents of the University of California and licensed to EarlyDiagnostics (Patent No. US20210125683A1). The other authors have no competing interests to declare.”